Project Grant HT94252410806
Award Date
9/1/24
Completion Date
8/31/28
Dollars Obligated
$1.7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award of $2,351,546 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2024, supports a research initiative by the University of Texas MD Anderson Cancer Center to investigate "Epigenetic Mechanism and Targeting During Response to BRAF/Anti-EGFR Therapy in BRAF-Mutant Colorectal Cancers". The research aims to explore the underlying epigenetic...
This federal Project Grant award of $1,622,612.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports preclinical validation of novel combination therapeutic strategies targeting KRAS and BRAF mutated colorectal cancer. The award was granted to The University of Texas M.D. Anderson Cancer Center to conduct this advanced biomedical research, with the goal of enabling near-term clinical examination of the developed therapies. The 3-year project...
The federal Project Grant award of $1,144,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research by the University of Texas MD Anderson Cancer Center to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (CCRCC). The award period runs from September 1, 2025, through August 31, 2028. MD Anderson, a...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
The federal Project Grant award of $728,043 was granted by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to The University of Texas M.D. Anderson Cancer Center in Houston, TX. The funding will support research to delineate the tumor ecology and genomic progression of lobular breast cancers over a period of 3 years from February 2025 to January 2028. This research aims to transform healthcare for military service members, veterans, and the...
The federal Project Grant award of $735,799.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to the University of Texas MD Anderson Cancer Center to support the project "INNOVATING BREAST CANCER RNA THERAPY: MECHANISMS AND PHARMACOGENETIC INHIBITORS". The project aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public,...
This federal Project Grant award of $613,125.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the University of Texas MD Anderson Cancer Center to develop EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative...
This Project Grant award, totaling $486,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports research conducted by the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to target PRMT5 in MTAP-loss melanoma. The project aims to transform health care for Service Members and the public through innovative and impactful cancer research, with a focus on...
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...